2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1492

Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1449

Microwave Radiometry As a Novel Additional Method for Rheumatoid Arthritis Disease Activity Assessment: A Prospective Single-Center Study

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1468

Minor Salivary Gland Biopsy: Its Importance in Rheumatoid Arthritis and Secondary Sjögren’s Syndrom

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1025

MiR-146a a Key Player in Bone Metabolism

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 1264

Modeling the Costs and Outcomes Associated with Treatment Sequences, with and without Tofacitinib, for Moderately to Severely Active Psoriatic Arthritis in the US

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1538

Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1009

Monocytes Membrane TNF Expression and Anti-TNF Treatment in Rheumatoid Arthritis

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 1171

Mortality Among Those with OA: Time-Varying Effects of Socioeconomic Measures

Epidemiology and Public Health Poster II – ARHP

9:00AM-11:00AM: Abstract Number: 1331

Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome

Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

9:00AM-11:00AM: Abstract Number: 1445

MRI Bone Erosions in RA Patients Relatives with Clinically Suspicious Arthralgia

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1789

Mucocutaneous Activity Index As a Patient-Reported Outcome Measure in Behcet’s Disease: A Multi-Center Study from Turkey

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1102

Multi-Organ RNA-Sequencing of Patients with Systemic Sclerosis (SSc) Finds That Intrinsic Subsets Are Conserved across Organ Systems

Systemic Sclerosis and Related Disorders – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 1737

Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1652

Musculoskeletal Involvement in Inflammatory Bowel Disease’S Patients: A Mono Centric Experience

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1205

Musculoskeletal Ultrasound and Conventional Radiography Evaluation of the Hip in Patients with Calcium Pyrophosphate Deposition Disease

Imaging of Rheumatic Diseases Poster II: Ultrasound

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].